Literature DB >> 11248056

A transcriptional corepressor of Stat1 with an essential LXXLL signature motif.

B Liu1, M Gross, J ten Hoeve, K Shuai.   

Abstract

Interferon (IFN) treatment induces tyrosine phosphorylation and nuclear translocation of Stat1 (signal transducer and activator of transcription) to activate or repress transcription. We report here that a member of the protein inhibitor of activated STAT family, PIASy, is a transcriptional corepressor of Stat1. IFN treatment triggers the in vivo interaction of Stat1 with PIASy, which represses Stat1-mediated gene activation without blocking the DNA binding activity of Stat1. An LXXLL coregulator signature motif located near the NH(2) terminus of PIASy, although not involved in the PIASy-Stat1 interaction, is required for the transrepression activity of PIASy. Our studies identify PIASy as a transcriptional corepressor of Stat1 and suggest that different PIAS proteins may repress STAT-mediated gene activation through distinct mechanisms.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11248056      PMCID: PMC30631          DOI: 10.1073/pnas.051489598

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  27 in total

1.  The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors.

Authors:  X Hu; M A Lazar
Journal:  Nature       Date:  1999-11-04       Impact factor: 49.962

Review 2.  The coregulator exchange in transcriptional functions of nuclear receptors.

Authors:  C K Glass; M G Rosenfeld
Journal:  Genes Dev       Date:  2000-01-15       Impact factor: 11.361

Review 3.  Modulation of STAT signaling by STAT-interacting proteins.

Authors:  K Shuai
Journal:  Oncogene       Date:  2000-05-15       Impact factor: 9.867

Review 4.  Complex roles of Stat1 in regulating gene expression.

Authors:  C V Ramana; M Chatterjee-Kishore; H Nguyen; G R Stark
Journal:  Oncogene       Date:  2000-05-15       Impact factor: 9.867

Review 5.  Association of STATs with relatives and friends.

Authors:  M Chatterjee-Kishore; F van den Akker; G R Stark
Journal:  Trends Cell Biol       Date:  2000-03       Impact factor: 20.808

6.  Mechanism of corepressor binding and release from nuclear hormone receptors.

Authors:  L Nagy; H Y Kao; J D Love; C Li; E Banayo; J T Gooch; V Krishna; K Chatterjee; R M Evans; J W Schwabe
Journal:  Genes Dev       Date:  1999-12-15       Impact factor: 11.361

7.  Regulation of c-myc expression by IFN-gamma through Stat1-dependent and -independent pathways.

Authors:  C V Ramana; N Grammatikakis; M Chernov; H Nguyen; K C Goh; B R Williams; G R Stark
Journal:  EMBO J       Date:  2000-01-17       Impact factor: 11.598

8.  Protein inhibitor of activated STAT-1 (signal transducer and activator of transcription-1) is a nuclear receptor coregulator expressed in human testis.

Authors:  J Tan; S H Hall; K G Hamil; G Grossman; P Petrusz; J Liao; K Shuai; F S French
Journal:  Mol Endocrinol       Date:  2000-01

9.  Distinct roles of the NH2- and COOH-terminal domains of the protein inhibitor of activated signal transducer and activator of transcription (STAT) 1 (PIAS1) in cytokine-induced PIAS1-Stat1 interaction.

Authors:  J Liao; Y Fu; K Shuai
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

10.  A signature motif in transcriptional co-activators mediates binding to nuclear receptors.

Authors:  D M Heery; E Kalkhoven; S Hoare; M G Parker
Journal:  Nature       Date:  1997-06-12       Impact factor: 49.962

View more
  56 in total

1.  PIASy, a nuclear matrix-associated SUMO E3 ligase, represses LEF1 activity by sequestration into nuclear bodies.

Authors:  S Sachdev; L Bruhn; H Sieber; A Pichler; F Melchior; R Grosschedl
Journal:  Genes Dev       Date:  2001-12-01       Impact factor: 11.361

Review 2.  Arginase: marker, effector, or candidate gene for asthma?

Authors:  Donata Vercelli
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

3.  Modification of the erythroid transcription factor GATA-1 by SUMO-1.

Authors:  Licio Collavin; Monica Gostissa; Fabio Avolio; Paola Secco; Antonella Ronchi; Claudio Santoro; Giannino Del Sal
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-01       Impact factor: 11.205

Review 4.  Biology and significance of the JAK/STAT signalling pathways.

Authors:  Hiu Kiu; Sandra E Nicholson
Journal:  Growth Factors       Date:  2012-02-20       Impact factor: 2.511

5.  PIASy inhibits virus-induced and interferon-stimulated transcription through distinct mechanisms.

Authors:  Toru Kubota; Mayumi Matsuoka; Songxiao Xu; Noriyuki Otsuki; Makoto Takeda; Atsushi Kato; Keiko Ozato
Journal:  J Biol Chem       Date:  2011-01-03       Impact factor: 5.157

Review 6.  SUMO wrestling with type 1 diabetes.

Authors:  Manyu Li; Dehuang Guo; Carlos M Isales; Decio L Eizirik; Mark Atkinson; Jin-Xiong She; Cong-Yi Wang
Journal:  J Mol Med (Berl)       Date:  2005-04-02       Impact factor: 4.599

Review 7.  Should we inhibit type I interferons in sepsis?

Authors:  Tina Mahieu; Claude Libert
Journal:  Infect Immun       Date:  2006-09-25       Impact factor: 3.441

8.  Physical and functional interactions of histone deacetylase 3 with TFII-I family proteins and PIASxbeta.

Authors:  María Isabel Tussié-Luna; Dashzeveg Bayarsaihan; Edward Seto; Frank H Ruddle; Ananda L Roy
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-18       Impact factor: 11.205

9.  Interplay between MITF, PIAS3, and STAT3 in mast cells and melanocytes.

Authors:  Amir Sonnenblick; Carmit Levy; Ehud Razin
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

10.  Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy.

Authors:  Jianjun Gao; Lewis Zhichang Shi; Hao Zhao; Jianfeng Chen; Liangwen Xiong; Qiuming He; Tenghui Chen; Jason Roszik; Chantale Bernatchez; Scott E Woodman; Pei-Ling Chen; Patrick Hwu; James P Allison; Andrew Futreal; Jennifer A Wargo; Padmanee Sharma
Journal:  Cell       Date:  2016-09-22       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.